Following testing by DNV at a rooftop project in the Italian city of Milan during January, it concluded that Trinasolar’s ...

Stifel Nicolaus downgraded shares of Vertex (NASDAQ:VERX – Free Report) from a buy rating to a hold rating in a report ...

Vertex (NASDAQ:VERX – Free Report) had its price target reduced by Robert W. Baird from $62.00 to $45.00 in a research report report published on Friday morning,Benzinga reports. Robert W. Baird ...

We recently compiled a list of the 10 Worst Performing Software Stocks to Buy According to Analysts. In this article, we are ...

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

The stock's rise snapped a four-day losing streak.

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.